What the research found

A randomized, placebo-controlled trial of NOVOS Core—a multi-ingredient supplement formulated to target aging processes—found measurable improvements in vascular function over six months. The supplement group showed better endothelial responsiveness (assessed via flow-mediated dilation, or FMD), reduced arterial stiffness (lower pulse wave velocity), and a larger drop in systolic blood pressure compared to placebo. Some effects appeared acutely within an hour of the first dose, while others became clearer over the six-month period.

The 61 participants were generally healthy, non-smoking adults, with about 43 completing the primary analysis. Each took 15 grams of powder daily containing glycine, calcium alpha-ketoglutarate, glucosamine sulfate, magnesium malate, vitamin C, L-theanine, fisetin, pterostilbene, hyaluronic acid, lithium aspartate, and extracts of rhodiola and ginger. The researchers measured vascular function at baseline, one hour after the first dose, and again at six months. No changes in blood lipid profiles were observed between groups, suggesting vascular improvements operated through mechanisms other than cholesterol modulation.

Why it matters for you

If you're tracking cardiovascular biomarkers via blood pressure cuff or considering pulse wave velocity measurements, this data suggests a multi-component supplement might meaningfully shift those numbers—particularly systolic pressure and arterial stiffness metrics. The FMD improvement (a measure of how well your arterial lining responds to blood flow changes) is notable because endothelial dysfunction is an early marker of atherosclerosis risk, even before plaque accumulates.

However, the vascular benefits here were independent of lipid changes, which matters if you've been optimizing LDL or triglycerides. It implies the supplement targets inflammation, oxidative stress, or mitochondrial function rather than cholesterol pathways. If you're on a training protocol designed to improve arterial compliance, or you're using blood pressure as a proxy for overall vascular aging, this could be worth tracking—though you'd need repeat testing to know if it works for you.

Caveats

• Industry-funded and supplied: NOVOS both provided the supplement/placebo and co-funded the study, creating potential bias in design or interpretation
• Small sample with high dropout: Only 43 of 61 participants completed the primary analysis; reasons for attrition were largely unexplained, which could skew results
• Age mismatch at baseline: The supplement group was on average 6–7 years younger, confounding interpretation of age-related improvements
• Surrogate endpoints only: Flow-mediated dilation and pulse wave velocity predict cardiovascular risk but don't prove the supplement prevents heart attacks or extends life
• Blood pressure measured minimally: Only two readings on two separate days; insufficient to characterise true chronic blood pressure changes
• Blended formulation: The trial tested the whole product, not individual ingredients, so it's unknown which components (if any) drive the effect
• Short follow-up: Six months is too brief to assess durability or long-term tolerability